ArriVent BioPharma, Inc.
AVBP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001868279
No open-market purchases or sales by ArriVent BioPharma, Inc. insiders were filed in the last 90 days; 157 institutions reported holding it in 13F filings for Q2 2026, worth $1.60B in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 10, 2026, 1:20 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | Mar 5, 2026 | Mar 3, 2025 |
| Operating expenses | $177.5M | $94.3M |
| Research and development | $153.4M | $79.0M |
| Selling, general and administrative | $24.2M | $15.3M |
| Operating income | -$177.5M | -$94.3M |
| Net income | -$166.3M | -$80.5M |
| EPS, basic | $-4.32 | $-2.56 |
| EPS, diluted | $-4.32 | $-2.56 |
| Weighted shares, basic | 38.5M | 31.5M |
| Weighted shares, diluted | 38.5M | 31.5M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | Mar 5, 2026 | Mar 3, 2025 |
| Cash and equivalents | $45.5M | $74.3M |
| Short-term investments | $267.3M | $144.6M |
| Total current assets | $332.9M | $227.0M |
| Total assets | $333.2M | $274.9M |
| Accounts payable | $5.93M | $3.78M |
| Total current liabilities | $25.9M | $17.3M |
| Total liabilities | $25.9M | $17.3M |
| Shareholders' equity | $307.2M | $257.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | Mar 5, 2026 | Mar 3, 2025 |
| Operating cash flow | -$160.6M | -$70.2M |
| Depreciation and amortization | -$3.03M | – |
| Stock-based compensation | $12.5M | $3.21M |
| Investing cash flow | -$71.2M | -$192.5M |
| Financing cash flow | $203.1M | $186.6M |
| Net change in cash | -$28.8M | -$76.1M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 5, 2026 | 51.7M | +25.3% | SEC |
| Aug 10, 2026 | 49.3M | +21.5% | SEC |
| May 8, 2026 | 46.6M | +36.1% | SEC |
| Mar 4, 2026 | 44.2M | +29.9% | SEC |
| Nov 7, 2025 | 41.3M | +22.5% | SEC |
| Aug 8, 2025 | 40.6M | +20.8% | SEC |
| May 9, 2025 | 34.2M | +2.1% | SEC |
| Feb 28, 2025 | 34.0M | – | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.